Spinal Muscular Atrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
If you are a patient:
- You have been diagnosed with ALS (in any confirmed stage or type), ALS with frontotemporal dementia (ALS-FTD), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), or you carry a known ALS gene mutation even if you have no symptoms yet (confirm with trial site)
- You have reached the legal age of adulthood in the province where you live or receive treatment
- You are able to understand and agree to take part in the study on your own
- You can read and communicate in English or French well enough to follow instructions and complete questionnaires
If you are a healthy volunteer (control participant):
- You are between 40 and 80 years old, or you are within 3 years of the age of a patient already enrolled in the study
- You have reached the legal age of adulthood in the province where you live or receive treatment
- You are able to understand and agree to take part in the study on your own
- You can read and communicate in English or French well enough to follow instructions and complete questionnaires
Who may not be able to join (healthy volunteers only):
- You have a history of a neurological condition affecting the brain or nervous system, such as stroke, head injury, epilepsy, nerve damage, or muscle disease
- You have been clinically diagnosed with a psychiatric condition such as depression or bipolar disorder, or you currently take medication for a psychiatric condition
- You are unable to have an MRI scan due to a pacemaker or any other reason not allowed by the study centre's MRI safety rules
- You experience significant claustrophobia (fear of enclosed spaces) that would prevent you from lying inside an MRI scanner for approximately one hour
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sanjay Kalra, MD, University of Alberta
Phone: 514-398-6188
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ALS Functional Rating Scale-Revised (ALSFRS-R); Forced Vital Capacity (FVC); Speech Testing; Neurological dysfunction as detected during standard neurological examination; Magnetic Resonance Imaging (MRI); Edinburgh Cognitive and Behavioural Screen (ECAS); ALS Assessment Questionnaire (ALSAQ-5); World Health Organization Quality of Life Questionnaire (WHO-QOL-BREF)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.